These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29601055)

  • 1. Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.
    Carter P; Alifrangis C; Cereser B; Chandrasinghe P; Del Bel Belluz L; Fotopoulou C; Frilling A; Herzog T; Moderau N; Tabassum N; Krell J; Stebbing J
    Oncotarget; 2018 Mar; 9(19):15164. PubMed ID: 29601055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.
    Carter P; Alifrangis C; Cereser B; Chandrasinghe P; Del Bel Belluz L; Fotopoulou C; Frilling A; Herzog T; Moderau N; Tabassum N; Krell J; Stebbing J
    Oncotarget; 2018 Jan; 9(5):6007-6014. PubMed ID: 29464050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.
    Carter P; Alifrangis C; Chandrasinghe P; Cereser B; Del Bel Belluz L; Leo CA; Moderau N; Tabassum N; Warusavitarne J; Krell J; Stebbing J
    Oncotarget; 2018 Mar; 9(19):15165. PubMed ID: 29601069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?
    Carter P; Alifrangis C; Cereser B; Chandrasinghe P; Del Bel Belluz L; Herzog T; Levitan J; Moderau N; Schwartzberg L; Tabassum N; Wen J; Krell J; Stebbing J
    Oncotarget; 2018 Mar; 9(19):15166. PubMed ID: 29601070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy.
    Hsu TI; Chen YJ; Hung CY; Wang YC; Lin SJ; Su WC; Lai MD; Kim SY; Wang Q; Qian K; Goto M; Zhao Y; Kashiwada Y; Lee KH; Chang WC; Hung JJ
    Oncotarget; 2019 Nov; 10(60):6536-6537. PubMed ID: 31741716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
    Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
    Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Gene function analysis and underlying mechanism of esophagus cancer based on microarray gene expression profiling.
    Yue Y; Song M; Qiao Y; Li P; Yuan Y; Lian J; Wang S; Zhang Y
    Oncotarget; 2020 Mar; 11(9):891-892. PubMed ID: 32180901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma.
    Ying Z; Shiue L; Park K; Kollet J; Bijani P; Goswami M; Duvic M; Ni X
    Oncotarget; 2019 Sep; 10(52):5492. PubMed ID: 31534633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
    Cazzaniga M; Verusio C; Ciccarese M; Fumagalli A; Sartori D; Valerio MR; Airoldi M; Moretti G; Ficorella C; Arcangeli V; Diodati L; Zambelli A; Febbraro A; Generali D; Pistelli M; Garrone O; Musolino A; Vici P; Maur M; Mentuccia L; La Verde N; Bianchi G; Artale S; Blasi L; Piezzo M; Atzori F; Turletti A; Benedetto C; Cursano MC; Fabi A; Gebbia V; Schirone A; Palumbo R; Ferzi A; Frassoldati A; Scavelli C; Clivio L; Torri V
    Oncotarget; 2018 Nov; 9(94):36720-36721. PubMed ID: 30613355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
    Cazzaniga M; Verusio C; Ciccarese M; Fumagalli A; Sartori D; Valerio MR; Airoldi M; Moretti G; Ficorella C; Arcangeli V; Diodati L; Zambelli A; Febbraro A; Generali D; Pistelli M; Garrone O; Musolino A; Vici P; Maur M; Mentuccia L; La Verde N; Bianchi G; Artale S; Blasi L; Piezzo M; Atzori F; Turletti A; Benedetto C; Cursano MC; Fabi A; Gebbia V; Schirone A; Palumbo R; Ferzi A; Frassoldati A; Scavelli C; Clivio L; Torri On Behalf Of The Eva Study Group V
    Oncotarget; 2018 Oct; 9(77):34639-34640. PubMed ID: 30349655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.
    Valentini D; Rao M; Meng Q; von Landenberg A; Bartek J; Sinclair G; Paraschoudi G; Jäger E; Harvey-Peredo I; Dodoo E; Maeurer M
    Oncotarget; 2018 Dec; 9(95):36817. PubMed ID: 30613370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Multiparametric imaging using
    Chan SC; Cheng NM; Hsieh CH; Ng SH; Lin CY; Yen TC; Hsu CL; Wan HM; Liao CT; Chang KP; Wang JJ
    Oncotarget; 2018 Feb; 9(11):10184. PubMed ID: 29517062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction: MiR-451 as a new tumor marker for gastric cancer.
    Shen Y; Gong JM; Zhou LL; Sheng JH
    Oncotarget; 2019 Oct; 10(59):6396. PubMed ID: 31695848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Metabolic pathway for the universal fluorescent recognition of tumor cells.
    Fernandez-Carrascal A; Garcia-Algar M; Nazarenus M; Torres-Nuñez A; Guerrini L; Feliu N; Parak WJ; Garcia-Rico E; Alvarez-Puebla RA
    Oncotarget; 2019 Nov; 10(61):6643. PubMed ID: 31762944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.
    Sandberg TP; Oosting J; van Pelt GW; Mesker WE; Tollenaar RAEM; Morreau H
    Oncotarget; 2019 Mar; 10(24):2416. PubMed ID: 31040931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Se
    Zhang HN; Feng WL; An CN; Li WG
    Oncotarget; 2018 Nov; 9(92):36542. PubMed ID: 30559936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Aug; 8(33):55766. PubMed ID: 28903459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.
    Alon M; Arafeh R; Lee JS; Madan S; Kalaora S; Nagler A; Abgarian T; Greenberg P; Ruppin E; Samuels Y
    Oncotarget; 2019 Feb; 10(13):1344. PubMed ID: 30863494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.
    Yu X; Ai J; Cai L; Jing Y; Wang D; Dong J; Pascal LE; Zhang J; Luo R; Wang Z
    Oncotarget; 2019 Dec; 10(67):7181-7182. PubMed ID: 31903175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment.
    Yuan H; Wang X; Lu J; Zhang Q; Brandina I; Alexandrov I; Glazer RI
    Oncotarget; 2018 Dec; 9(102):37808. PubMed ID: 30701035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.